MXCT - MAXCYTE, INC.

0.6762
-0.007   -1.094%

Share volume: 883,931
Last Updated: 03-30-2026
Business Services/Services – Research, Development, Testing Labs: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$0.68
-0.01
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 22%
Liquidity 70%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.66%
1 Month
-11.05%
3 Months
-56.37%
6 Months
-57.74%
1 Year
-75.23%
2 Year
-80.90%
Key data
Stock price
$0.68
P/E Ratio 
N/A
DAY RANGE
$0.66 - $0.69
EPS 
-$0.40
52 WEEK RANGE
$0.64 - $2.96
52 WEEK CHANGE
-$75.05
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
106.861 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$1,126,770
AVERAGE 30 VOLUME 
$1,033,309
Company detail
CEO: Douglas A. Doerfler
Region: US
Website: maxcyte.com
Employees: 80
IPO year: 2019
Issue type:
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services

MaxCyte, Inc. engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Recent news